Already a DIA Member? Sign in. Not a member? Join.

Sign in

Forgot User ID? or Forgot Password?

Not a Member?

Create Account and Join

Conrad Cairo Hotel

Nov 25, 2024 6:00 PM - Nov 27, 2024 6:00 PM

1191 Nile Corniche, Cairo, 11221, Egypt

Middle East and North Africa Conference (MENA)

Session 8: Suppy Chain & Sample Management

Session Chair(s)

Joerg  Garbe, PHD, MSC

Joerg Garbe, PHD, MSC

IFPMA In-Country Testing Taskforce Lead; Global Quality Manager & Policy Lead, F. Hoffmann-La Roche Ltd, Switzerland

Doaa  Rady

Doaa Rady

Lot Release administration manager, Egyptian Drug Authority (EDA), Egypt

This Session will explore the global trend of using a Reliance-based waiver for in-country testing. Regulators will share their practical experiences with risk-based surveillance testing to replace import/registration testing. The goal of this session is to support regulators in the MENA region in optimising their testing systems to avoid waste of resources and ensure no delay of drug supply to patients.

Speaker(s)

Joerg  Garbe, PHD, MSC

Introduction: Global Trends and Regional Perspective

IFPMA In-Country Testing Taskforce Lead; Global Quality Manager & Policy Lead, F. Hoffmann-La Roche Ltd, Switzerland

Rutendo  Kuwana, RPH

WHO - Reliance for Sample Testing

Team Lead, Incidents and Substandard/Falsified Medical Products, World Health Organization (WHO), Switzerland

Rania  Elafifi

Regional Perspective on In-Country Testing

Regulatory Affairs Lead - Egypt, Roche, Egypt

Doaa  Rady

Practical Implementation of Risk-Based Strategies and Optimized Testing Systems in Egypt

Lot Release administration manager, Egyptian Drug Authority (EDA), Egypt

Pavle  Zelic

Risk-based Surveillance Testing in Serbia and How it Complements Anti-Counterfeit Activities in Serbia

International Cooperation, European Integrations and Public Relations, Medicines and Medical Devices Agency of Serbia (ALIMS), Serbia

Rana  Malkawi

Panel Discussion with QandA, with the additional participation of:

Drug Directorate Director, Jordan Food and Drug Administration (JFDA), Jordan

Agnes  Chan

Panel Discussion with QandA, with the additional participation of:

Director, Therapeutic Products Branch, Health Sciences Authority, Singapore, Singapore

Have an account?

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.